Pfizer has paid nearly $1 billion to settle class actions and other lawsuits involving Neurontin.
Pfizer Pays $325 Million to Settle Neurontin Class Action Lawsuits
In June 2014, Pfizer has reached a $325 million class action lawsuit settlement over allegations that Neurontin was fraudulently marketed. The settlement ends a nearly 10-year-old battle in which plaintiffs accused Pfizer of protecting their monopoly on the drug by suppressing generic alternatives.
In April 2014, Pfizer agreed to pay a $190 million settlement to end a class action lawsuit with direct purchasers (consumers) of the drug.
Members of the litigation also accused Pfizer of promoting Neurontin for unapproved uses. In 2004, the Justice Department ordered the drug-maker to pay $430 million to resolve civil and criminal allegations of illegally marketing Neurontin “off-label” for bipolar disorder, migraines, and more.